Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Shoryo Hayashi is active.

Publication


Featured researches published by Shoryo Hayashi.


Peptides | 1991

Brain transfer of a new neuromodulating ACTH analog, ebiratide, in rats.

Takesada Shimura; Shigeru Tabata; Shoryo Hayashi

The transfer of ebiratide into the brain was examined in rats. Its brain levels after intravenous administration (2-20 mg/kg), determined by radioimmunoassay, peaked at 5 min and declined almost in parallel with the plasma levels. Brain/plasma ratios (B/P) were constantly about 0.05 ml/g at all doses. Brain distribution study at 5 min after 125I-ebiratide at an effective dose (0.4 microgram/kg) revealed that unchanged ebiratide had larger B/P than the metabolites and region selectivity. The combined use with unlabeled ebiratide resulted in marked decreases in B/P, particularly in the hippocampus, suggesting a specific uptake of this peptide.


Life Sciences | 1988

Analgesia and plasma β-endorphin-like immunoactivity in compound 4880-induced hypovolemia of the rats

Hiroshi Izumi; Shoryo Hayashi; Keisiro Karita

The effects of subcutaneous (s.c.) administration of compound 48/80 (a well known histamine liberator) on latency to thermoalgesic stimulus, hematocrit (Hct) and plasma levels of beta-endorphin-like immunoreactivity (beta-END-LI) were investigated in male rats. The s.c. administration of compound 48/80 in doses ranging from 0.5 to 5.0 mg/kg into the rats produced significant analgesia in the hot plate test and increased Hct in a dose-dependent manner. Concomitant variation was observed between the analgesia and the increase of Hct. This analgesic effect, but not the increase of Hct, was diminished by pretreatment with the opiate receptor antagonist, naloxone (5 mg/kg, s.c.). A significant increase of plasma beta-END-LI was observed by s.c. injection of compound 48/80. Together with a previous finding that compound 48/80 induced-hypovolemia increases the renin release from kidney and then causes water intake in the rats, it is suggested that s.c. administration of compound 48/80 induced analgesia mediated through stimulation of an opioid system, may be closely related to stimulation of the renin-angiotensin system.


General Pharmacology-the Vascular System | 1989

The role of renin-angiotensin system in compound 4880-induced analgesia in rats

Hiroshi Izumi; Shoryo Hayashi

1. The antinociceptive effect of compound 48/80 was reversed by the pretreatment with an angiotensin-converting enzyme (ACE) inhibitor, Hoe 498, in a dose-dependent manner and with a opiate receptor antagonist, naloxone (5.0 mg/kg, s.c.) in rats. 2. The increase of plasma beta-endorphin-like immunoreactivity produced through s.c. administration of compound 48/80 was attenuated by the pretreatment with Hoe 498 but not with naloxone. 3. The present data suggest the possible involvement of renin-angiotensin system in compound 48/80-induced analgesia in rats.


Folia Pharmacologica Japonica | 1992

[Antihypertensive effect of felodipine, a new calcium antagonist].

Tsutomu Inoue; Mikio Omosu; Shoryo Hayashi; Sigeki Sakaguchi; Kenzo Nakao; Toshiya Inukai; Norio Odagiri; Teiji Ono

The antihypertensive effect of felodipine was examined in various hypertensive animal models. In spontaneously hypertensive rats, felodipine administered singly at 0.1-1.0 mg/kg (p.o.) had a dose-dependent antihypertensive effect. Nifedipine was effective at 1 mg/kg. In the repeated oral administration experiment, both the maximum decrease in blood pressure and duration of the effect increased gradually and reached steady levels at 3 weeks of administration, which were maintained thereafter. Similar results were noted with nifedipine, but felodipine was longer-acting (4-6 hr) in the steady state than nifedipine (1-2 hr). No development of tolerance was observed during the administration period. In DOCA-salt and renal hypertensive (2K1C) rats, felodipine at 0.1-0.5 mg/kg (p.o.) was superior to nifedipine in the maximum decrease in blood pressure and duration of the effect. Felodipine up to 1 mg/kg (p.o.) caused no significant heart rate increase in any rat model. In renal hypertensive (2K2C) dogs given felodipine at 0.2-0.5 mg/kg (p.o.), the effect lasted for 2 hr after injection. This felodipine effect was stronger and longer lasting than the nifedipine one. At 0.5 mg/kg of felodipine, the heart rate was transiently increased. The present results show that felodipine has a stronger and long-lasting antihypertensive effect than nifedipine in the hypertension models.


Experimental Animals | 1978

A Micro-Method Developed for Prothrombin Time Assay

Mitsuo Takizawa; Ryuji Yajima; Shoryo Hayashi; Takashi Sakaguchi

Prothrombin time was measured by a newly developed micro-method using a plastic film available in the market (PARAFILM, American Can. Co.). The comparative study of this micro-method with that of Quick in rats disclosed a good correlation, with correlation coefficient of 0.951, supporting the usefulness of the method for examination of blood coagulability. The new method gave the physiological values of 9.8 sec in rabbits, 12.5 sec in dogs, 13.3 sec in mice, 14.8 sec in cats and 16.0 sec in rats, respectively. Among them, guinea pigs took the longest time of 25.3 sec for the coagulation.


Chemical & Pharmaceutical Bulletin | 1974

Studies on 3,7-dimethyl-1-(5-oxo-hexyl)-xanthine(BL 191). I. Cyclic 3',5'-nucleotide phosphodiesterase (PDE) and the inhibitory effect of BL 191 on PDE in rat brain and heart.

Shoryo Hayashi; Hikaru Ozawa


Chemical & Pharmaceutical Bulletin | 1967

Studies on Proteases in Submaxillary Gland. I. Fractionation and General Characteristics of Rat Submaxillary Proteases.

Akira Minato; Seiyu Hirose; Shoryo Hayashi


Chemical & Pharmaceutical Bulletin | 1974

Pharmacokinetic Investigation of 17α-Desoxymethasone (A 41 304) in Rats

Shoryo Hayashi; Takashi Sakaguchi; Hikaru Ozawa


Experimental Animals | 1979

The Incidences of Spontaneous Fetal Anomalies in Japanese White Rabbits

Takashi Sugisaki; Mieko Iijima; Kazuo Takayama; Shoryo Hayashi; Masaki Miyamoto


Chemical & Pharmaceutical Bulletin | 1975

Antispasmodic action of 1-diethylaminoethyl-3-(p-methoxybenzyl)-2-quinoxalone (P 201-1) and its inhibitory effect on cyclic 3',5'-nucleotide phosphodiesterase (PDE) activity.

Shoryo Hayashi; Hikaru Ozawa

Collaboration


Dive into the Shoryo Hayashi's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Akira Minato

Taisho Pharmaceutical Co.

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge